Park National Corp OH Lowers Stock Position in Becton, Dickinson and Company (NYSE:BDX)


Share on StockTwits

Park National Corp OH lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,444 shares of the medical instruments supplier’s stock after selling 95 shares during the quarter. Park National Corp OH’s holdings in Becton, Dickinson and were worth $837,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in BDX. Flagship Private Wealth LLC purchased a new position in Becton, Dickinson and during the fourth quarter worth about $25,000. Dimension Capital Management LLC purchased a new position in Becton, Dickinson and during the third quarter worth about $29,000. Kempen Capital Management N.V. purchased a new position in Becton, Dickinson and during the fourth quarter worth about $29,000. Sage Private Wealth Group LLC purchased a new position in Becton, Dickinson and during the fourth quarter worth about $37,000. Finally, Fort Pitt Capital Group LLC purchased a new position in Becton, Dickinson and during the fourth quarter worth about $38,000. 83.22% of the stock is owned by institutional investors.

Shares of NYSE:BDX opened at $244.02 on Thursday. The firm’s 50 day moving average price is $243.71 and its 200 day moving average price is $243.60. The stock has a market cap of $70.90 billion, a price-to-earnings ratio of 89.38, a price-to-earnings-growth ratio of 2.34 and a beta of 0.79. Becton, Dickinson and Company has a fifty-two week low of $219.50 and a fifty-two week high of $284.97. The company has a quick ratio of 1.07, a current ratio of 1.54 and a debt-to-equity ratio of 0.72.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Wednesday, February 3rd. The medical instruments supplier reported $4.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $1.41. The business had revenue of $5.32 billion for the quarter, compared to analyst estimates of $4.87 billion. Becton, Dickinson and had a net margin of 5.11% and a return on equity of 13.30%. The company’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same period last year, the firm posted $2.65 earnings per share. On average, equities analysts anticipate that Becton, Dickinson and Company will post 12.5 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 31st. Stockholders of record on Wednesday, March 10th were given a dividend of $0.83 per share. The ex-dividend date of this dividend was Tuesday, March 9th. This represents a $3.32 dividend on an annualized basis and a dividend yield of 1.36%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 32.55%.

Several brokerages have recently issued reports on BDX. Citigroup increased their price target on shares of Becton, Dickinson and from $273.00 to $280.00 and gave the stock a “neutral” rating in a research report on Friday, February 5th. Wells Fargo & Company cut shares of Becton, Dickinson and from an “overweight” rating to an “equal weight” rating and set a $265.00 price target on the stock. in a research report on Tuesday, December 15th. Zacks Investment Research cut shares of Becton, Dickinson and from a “buy” rating to a “hold” rating and set a $276.00 price target on the stock. in a research report on Wednesday, January 13th. The Goldman Sachs Group cut shares of Becton, Dickinson and from a “conviction-buy” rating to a “buy” rating in a research report on Tuesday, December 15th. Finally, Piper Sandler increased their price target on shares of Becton, Dickinson and from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 4th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Becton, Dickinson and currently has an average rating of “Buy” and a consensus price target of $281.08.

About Becton, Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Shanghai Stock Exchange Composite Index

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.